Use of Immune Profiling Panel to assess the immune response of septic patients for prediction of worsening as a composite endpoint.

Autor: Peronnet E; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France. estelle.peronnet@biomerieux.com.; Open Innovation and Partnerships (OI&P), bioMérieux S.A., Marcy-l'Etoile, France. estelle.peronnet@biomerieux.com., Terraz G; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France.; EFOR, Champagne-au-Mont-d'Or, France., Cerrato E; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France.; Open Innovation and Partnerships (OI&P), bioMérieux S.A., Marcy-l'Etoile, France., Imhoff K; Data Science, bioMérieux S.A., Marcy l'Etoile, France., Blein S; Data Science, bioMérieux S.A., Marcy l'Etoile, France., Brengel-Pesce K; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France.; Open Innovation and Partnerships (OI&P), bioMérieux S.A., Marcy-l'Etoile, France., Bodinier M; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France.; Open Innovation and Partnerships (OI&P), bioMérieux S.A., Marcy-l'Etoile, France., Fleurie A; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France.; Open Innovation and Partnerships (OI&P), bioMérieux S.A., Marcy-l'Etoile, France., Rimmelé T; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France.; Anaesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France., Lukaszewicz AC; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France.; Anaesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France., Monneret G; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France.; Immunology Laboratory, Edouard Herriot Hospital - Hospices Civils de Lyon, Lyon, France., Llitjos JF; Joint Research Unit HCL-bioMérieux, EA 7426 'Pathophysiology of Injury-Induced Immunosuppression' (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon, bioMérieux), Lyon, France.; Open Innovation and Partnerships (OI&P), bioMérieux S.A., Marcy-l'Etoile, France.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 May 17; Vol. 14 (1), pp. 11305. Date of Electronic Publication: 2024 May 17.
DOI: 10.1038/s41598-024-62202-z
Abstrakt: Sepsis induces intense, dynamic and heterogeneous host response modulations. Despite improvement of patient management, the risk of mortality and healthcare-associated infections remains high. Treatments to counterbalance immune response are under evaluation, but effective biomarkers are still lacking to perform patient stratification. The design of the present study was defined to alleviate the limitations of existing literature: we selected patients who survived the initial hyperinflammatory response and are still hospitalized at day 5-7 after ICU admission. Using the Immune Profiling Panel (IPP), a fully automated RT-qPCR multiplex prototype, we optimized a machine learning model combining the IPP gene expression levels for the identification of patients at high risk of worsening, a composite endpoint defined as death or secondary infection, within one week after sampling. This was done on 332 sepsis patients selected from two retrospective studies. The IPP model identified a high-risk group comprising 30% of patients, with a significant increased proportion of worsening events at day 28 compared to the low-risk group (49% vs. 28%, respectively). These preliminary results underline the potential clinical application of IPP for sepsis patient stratification in a personalized medicine perspective, that will be confirmed in a larger prospective multicenter study.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje